Notably, the AKT inhibitor triciribine alone had a cytostatic effect on tumor cells but did not preferentially inhibit CD133+ tumor-initiating cells, whereas the PPARγ agonist rosiglitazone selectively targeted HCC TICs. Here, PPARG is linked to hepatocellular carcinoma.